Moderna Cancer Vaccine Progress Adds $44 Billion to Market Value

In August 2026, Moderna saw its market value rise by about $44 billion from a prior low, driven by its long-term push in cancer vaccines. Since launching its personalized cancer vaccine research program in 2015, the company has developed two candidates, SPC and mRNA-4157, with the latter entering Phase III clinical trials for high-risk melanoma patients in December 2023.

mRNA technology first drew wide attention through COVID-19 vaccines, but cancer vaccine development faces multiple technical challenges, including tumor-specific antigen screening and delivery-system optimization. Moderna's approach relies on genetic sequencing of patient tumors to identify neoantigens, then designing mRNA sequences to trigger a personalized immune response. Phase II trial data released in late 2024 showed that the vaccine, when combined with a PD-1 inhibitor, reduced the risk of recurrence or death in high-risk melanoma patients by about 44%.

The company has entered a collaboration with Merck to jointly advance the therapy's clinical development and commercialization. According to public information, since the Phase III trial began in 2023, the research team has completed patient enrollment at multiple clinical centers in the United States, Europe, and Australia, with relapse-free survival as the primary endpoint.